光子与质子治疗诱导的正常组织损伤:空白与机会
本文综述了光子与质子放疗正常组织损伤的临床研究现状:注册于ClinicalTrials.gov的质子试验多为小样本非随机早期研究;三项近期完成的随机试验显示,早期NSCLC因入组低无法比较,局部晚期NSCLC质子未优于光子,局部晚期食管癌质子总毒性负担较低但未改善无进展生存和生活质量。
要点
- 质子治疗剂量学优势明确,毒性谱有利,但 randomized 证据有限。
- 早期NSCLC的SBRT与SBRT质子比较因入组低无法进行。
- 局部晚期食管癌质子总毒性负担较低,但未改善PFS和QoL。
核心结论
- 现有数据支持质子治疗的剂量学优势和有利毒性谱,但需进一步开展对比性随机前瞻试验。
- 对质子与光子放射生物学差异的基础理解是确定生物优化放疗适用性的必要前提。
研究设计与样本
- 本综述分析了ClinicalTrials.gov注册的临床试验和PubMed中质子治疗相关文献两个数据库。
- 注册于ClinicalTrials.gov且有结果的质子治疗研究多为非随机早期试验,入组患者数相对较少。
主要发现
- PubMed中质子治疗文献发表数量呈稳定增长。
- 早期非小细胞肺癌的立体定向体部放疗与立体定向体部质子治疗因入组低(NCT01511081)无法进行有意义的比较。
- 局部晚期非小细胞肺癌中,调强放疗与被动散射质子治疗比较,质子未在正常组织毒性或局部区域失败方面优于光子。
- 局部晚期食管癌中,质子束治疗提供较低的总毒性负担,但未改善无进展生存和生活质量(NCT01512589)。
关键数值与推荐
- 早期非小细胞肺癌试验NCT01511081因入组低无法比较SBRT与SBRT质子治疗。
- 局部晚期非小细胞肺癌中被动散射质子治疗未显示正常组织毒性或局部区域失败优于光子。
- 局部晚期食管癌试验NCT01512589中质子束治疗总毒性负担较低,但无进展生存和生活质量未改善。
临床怎么用
- 质子治疗可用于改善毒性谱,但需结合放射生物学差异选择适合的患者或队列。
- 未来试验应聚焦精准放疗,并将技术进步视为迭代过程。
局限性
- 多数质子治疗注册研究为非随机早期试验,入组患者数较少。
- 部分随机试验因入组低无法完成有意义的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite technological advances in radiation therapy (RT) and cancer treatment, patients still experience adverse effects. Proton therapy (PT) has emerged as a valuable RT modality that can improve treatment outcomes. Normal tissue injury is an important determinant of the outcome; therefore, for this review, we analyzed 2 databases: (1) clinical trials registered with ClinicalTrials.gov and (2) the literature on PT in PubMed, which shows a steady increase in the number of publications. Most studies in PT registered with ClinicalTrials.gov with results available are nonrandomized early phase studies with a relatively small number of patients enrolled. From the larger database of nonrandomized trials, we listed adverse events in specific organs/sites among patients with cancer who are treated with photons and protons to identify critical issues. The present data demonstrate dosimetric advantages of PT with favorable toxicity profiles and form the basis for comparative randomized prospective trials. A comparative analysis of 3 recently completed randomized trials for normal tissue toxicities suggests that for early stage non-small cell lung cancer, no meaningful comparison could be made between stereotactic body RT and stereotactic body PT due to low accrual (NCT01511081). In addition, for locally advanced non-small cell lung cancer, a comparison of intensity modulated RT with passive scattering PT (now largely replaced by spot-scanned intensity modulated PT), PT did not provide any benefit in normal tissue toxicity or locoregional failure over photon therapy. Finally, for locally advanced esophageal cancer, proton beam therapy provided a lower total toxicity burden but did not improve progression-free survival and quality of life (NCT01512589). The purpose of this review is to inform the limitations of current trials looking at protons and photons, considering that advances in technology, physics, and biology are a continuum, and to advocate for future trials geared toward accurate precision RT that need to be viewed as an iterative process in a defined path toward delivering optimal radiation treatment. A foundational understanding of the radiobiologic differences between protons and photons in tumor and normal tissue responses is fundamental to, and necessary for, determining the suitability of a given type of biologically optimized RT to a patient or cohort.
引用
- Prasanna PG, Rawojc K, Guha C, et al. Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities. Int J Radiat Oncol Biol Phys. 2021. PMID: 33640423. doi:10.1016/j.ijrobp.2021.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。